Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic score~* Evidence of colonic ulcerative colitis activity on endoscopy~Exclusion Criteria:~* Within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a non-biologic investigational therapy or an approved non-biologic therapy in an investigational protocol~* Within 60 days prior to randomization, receipt of any of the following: Infliximab, adalimumab, golimumab, certolizumab, vedolizumab, any other investigational or approved biologic agent~* Any prior exposure to natalizumab, efalizumab, or rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod Low Dose (Type: EXPERIMENTAL): Oral, low dose, daily for 12 Weeks
- Etrasimod High Dose (Type: EXPERIMENTAL): Oral, high dose, daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Oral, placebo, daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).